Fox Run Management’s Climb Bio CLYM Stock Holding History

Fox Run Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,287	Closed	-$126K	–	1364
2026 Q1	$126K	Buy	+19,287	New	+$111K	0.02%	822

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fox Run Management's CLYM Position: Q2 2026 in Review

Fox Run Management sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 19,287 shares — an estimated $126K sold.

Fox Run Management first reported a position in CLYM in Q1 2026 and held it in 1 quarter. The position peaked at $126K in Q1 2026. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Fox Run Management reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
Fox Run Management sold 19,287 Climb Bio shares in Q2 2026, an estimated $126K.
Fox Run Management first reported a position in Climb Bio in Q1 2026 and held it in 1 quarter.
Fox Run Management's Climb Bio position peaked at $126K in Q1 2026.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.